Heike Richly

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

Dirk Strumberg, Heike Richly, Ralf A. Hilger et al. · Journal of Clinical Oncology · 2004 · 870 citations · Full text

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

Dirk Strumberg, M. E. Scheulen, Beate Schultheis et al. · British Journal of Cancer · 2012 · 252 citations · Full text

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study

Martin Schüler, Byoung Chul Cho, Cyrus Sayehli et al. · The Lancet Oncology · 2019 · 161 citations

Fgfr Mrna Expression, Oncology, Medicine +8

A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancer

Uğur Şahin, Martin Schüler, Heike Richly et al. · European Journal of Cancer · 2018 · 155 citations · Full text

Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors

Heike Richly, Bernhard F. Henning, P. Kupsch et al. · Annals of Oncology · 2006 · 142 citations · Full text

Medicine, Pharmacology, Pathology +8